Compare Hasbro, Inc. (HAS) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hasbro, Inc. vs Sana Biotechnology Inc — how do they compare? Hasbro, Inc. trades at $94.24 (market cap $13.05B), while Sana Biotechnology Inc trades at $2.83 (market cap $836.71M). The key difference: Hasbro, Inc. is far larger — about 15.6× Sana Biotechnology Inc's market cap, and Hasbro, Inc. pays a 3.03% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hasbro, Inc. for 97 Days and Sana Biotechnology Inc for 23 Days on average.
| HAS | SANA | |
|---|---|---|
Market Cap | $13.05B | $836.71M |
Volume | 1,207,655 | 4,507,444 |
Sector | Consumer Cyclical | Health |
52-Week High | $105.88 | $5.92 |
52-Week Low | $70.95 | $2.68 |
Typical Hold Time | 97 Days | 23 Days |
Enterprise Value | $15.24B | $749.96M |
Dividend Yield | 3.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hasbro (HAS) trades at $90.75, down 0.31% on the day, with strong technical momentum showing bullish moving average signals and key support at $90. The company demonstrates robust profitability with 64.41% gross margins and has beaten earnings estimates for three consecutive quarters, though 2025 showed a net loss of $322.4 million. Analyst consensus remains positive with a $107.60 price target and no sell ratings among 33 analysts.
Outlook remains constructive with projected 2026 revenue growth to $5.0B and net income of $794M, supported by Magic: The Gathering's strong performance. Key risks include high debt levels at 59.09% debt-to-asset ratio and competitive pressures in the toy industry. The stock offers 18.5% upside to consensus target with institutional ownership showing mixed positioning.
SANA Biotechnology trades at $2.83, up 4.04% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue generation, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent investor conference presentations highlight ongoing business development activities.
Despite 82% analyst buy ratings and a $9.50 consensus price target, SANA carries high risk due to pre-revenue status, negative cash flow, and shareholder litigation concerns. The stock's investment case hinges on successful clinical development and future commercialization of its engineered cell therapies, requiring careful risk assessment by investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hasbro, Inc.
Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. Ownership stakes in Discovery Family, which offers programming around Hasbro brands, and owned production capabilities from Entertainment One help bolster Hasbro's multichannel presence. The firm acquired Entertainment One in 2019, bolting on popular properties like Peppa Pig and PJ Masks, and has plans to tie up with Dungeons & Dragons Beyond in 2022, offering the firm access 10 million digital tabletop players.
Read more on HAS →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
